Observational studyCritical care (London, England)2026
Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study.
Observational study in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpreting viral severe acute respiratory infection in critically ill immunocompromised patients: phenotype, co-infections, and severity.Critical care (London, England) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to compare the clinical characteristics, treatments and outcomes of immunocompromised patients with viral severe acute respiratory infections (SARI), to those of immunocompetent patients admitted to an intensive care unit (ICU) across Australia.
methodsRetrospective analysis of a prospective, nation-wide, observational registry of 46 ICUs from June 2022 to August 2025. Critically ill adults (age ≥ 18) with laboratory-confirmed viral SARI were included. Immunocompromised status was defined by the presence of any one of the following: chronic immunosuppression, malignant neoplasm, AIDS/HIV, or organ transplantation. Associations between immunocompromised status and in-hospital mortality were evaluated using mixed-effects logistic regression models. Competing risks regression (Fine and Gray models) was used to assess the association between immunocompromised status and risk of hospital discharge within 30 days.
resultsAmong 4,703 patients with viral SARI who were admitted to ICUs, immunocompromised patients accounted for 908 (19.3%) cases. Immunocompromised patients were older (median age 67 vs. 62 years), more comorbid (31.4% vs. 22.5% with ≥ 3 comorbidities), and more frequently admitted with COVID-19 (51.1% vs. 34.5%); (p < 0.001 for all). Immunocompromised patients received more treatment, including antivirals (67.3% vs. 57.7%), and corticosteroids (81.7% vs. 72%) and had higher in-hospital mortality (22.7% vs. 13.1%); (p < 0.01 for all). After adjusting for demographics, comorbidities, vaccination status (where available), ICU interventions and treatments, immunocompromised status was independently associated with nearly double the odds of in-hospital mortality (adjusted OR 1.93, 95% CI 1.57-2.37).
conclusionsIn this study, we found that immunocompromised patients accounted for approximately one-fifth of critically ill viral SARI patients and had nearly twice the odds of in-hospital mortality, when compared to those that were immunocompetent. Targeted public health campaigns and improved treatment strategies may be warranted for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.